To explore the safety and efficacy of intervention therapy for mild ischemic stroke patients with large vessel occlusion (LVO-MIS) and identify factors influencing the prognosis of LVO-MIS patients. Methods: Seventy-nine patients with LVO-MIS were retrospectively included from January 2020 to September 2023 at the Department of Neurology, Puren Hospital, Wuhan University of Science and Technology. They were divided into two groups based on the treatment method: 30 cases in the interventional therapy group and 49 cases in the medication-only group. The primary endpoints were the neurological recovery at day 90, assessed by the modified Rankin scale (mRS) score (mRS≤1 defined as excellent prognosis, mRS 1～2 as good prognosis, and mRS>2 as poor prognosis). Secondary outcomes included post-treatment revascularization, early neurological deterioration, symptomatic intracranial hemorrhage and mortality. Logistic regression was used to identify factors affecting the prognosis of patients with LVO-MIS. Results: Twenty-eight patients in the interventional therapy group achieved successful recanalization of blood vessels (93.3% ). At 90 days after treatment, the rate of excellent prognosis was significantly higher in the interventional therapy group than in the medication-only group (P=0.022). There were no statistically significant differences between the two groups regarding early neurological deterioration, symptomatic intracranial hemorrhage and morbidity and mortality (P> 0.05). Multivariate Logistic analysis results showed that interventional therapy (P<0.05) was an independent protective factor for achieving an excellent prognosis in LVO-MIS patients at 90 days postoperatively. Additionally, the NIHSS score at admission and time from onset to admission (all P<0.05) were independent risk factors for excellent prognosis in LVO-MIS patients at 90 days postoperatively. Conclusion: Interventional therapy is safe and effective in improving the prognosis of patients with LVO-MIS, without significantly increasing the risk of adverse events such as postoperative symptomatic intracranial hemorrhage and mortality.